［EN］"Loved" vs. "Can't Live Without" — What Two ¥1 Trillion Drug Store Giants Teach Us About Brand Strategy【Japan 2026】

A deep dive into the latest earnings of MatsuKiyo CC & Sugi Holdings — comparing growth strategies through a brand growth lens

Let's Start With a Surprising Story

In the spring of 2026, something historic happened in Japan's drug store industry.

Sugi Holdings (Sugi Pharmacy) crossed ¥1 trillion in annual sales for the very first time.

To put that in perspective: if every person in Japan spent ¥8,000 at Sugi Pharmacy in a year, that would be roughly ¥1 trillion. Of course, that's not literally what happened — but it gives you a sense of the sheer scale we're talking about.

And with Matsumoto Kiyoshi Cocokara & Company (MatsuKiyo CC) — which had already surpassed the ¥1 trillion mark — now joined by Sugi, Japan suddenly has two ¥1 trillion drug store companies standing side by side.

But here's what makes this story really interesting: these two companies took completely opposite paths to get there.

One built a brand that people love and actively seek out. The other built something so deeply embedded in people's daily lives that they simply can't leave. Two different strategies, same extraordinary result.

Let's break it down.

The Numbers: A Quick Look at Both Companies

MatsuKiyo CC (FY2026, ended March 2026)

MetricResultYoY ChangeNet Sales¥1,117.4B＋5.3%Operating Profit¥84.9B＋3.5%Ordinary Profit¥89.8B＋4.2%Net Income¥55.7B＋2.0%

Record profits for the 6th consecutive year. The company also projects further growth next fiscal year, and raised its annual dividend by ¥6 to ¥56 per share — a clear signal of confidence in its trajectory.

Sources: Kabutan News (May 13, 2026), Nikkei Shimbun (May 13, 2026)

Sugi Holdings (FY2026, ended February 2026)

MetricResultYoY ChangeNet Sales¥1,010.3B＋15.1%Operating Profit¥48.5B＋14.1%Ordinary Profit¥50.0B＋19.2%Net Income¥44.9B＋75.1%

First-ever ¥1 trillion in sales — a milestone for the company. One quick note on the ＋75.1% net income jump: it's partly inflated by a one-time deferred tax asset recorded as part of the merger with dispensing pharmacy chain I&H. Net income is projected to fall 27.1% next year, so operating and ordinary profit are the better measures of underlying performance.

Sources: Ryutsu News (April 9, 2026), Nikkei Shimbun (April 10, 2025)

MatsuKiyo CC: The "We Want to Shop Here" Brand

Cosmetics Are Now the Core Business

Ask yourself: what do you picture when you think of MatsuKiyo? Probably cosmetics.

That intuition is backed by data. In FY2026, cosmetics sales grew ＋7.9% to ¥381.2B — outpacing pharmaceutical sales growth (＋5.1%). The "beauty and health" category now makes up 72.4% of total sales (up 0.9 points year-on-year), and gross profit margin improved 0.3 points to 36.1%.

MatsuKiyo is quietly transforming from "the pharmacy" into something closer to a curated beauty and wellness destination. And that shift is deliberate.

Source: WWD Japan (May 13, 2026)

Inbound Tourists Are Choosing MatsuKiyo — and Posting About It

Japan's tourism boom is real, and MatsuKiyo is one of its biggest beneficiaries. With stores concentrated in urban centers, train stations, and shopping complexes, the company is perfectly positioned to capture inbound consumer spending from international visitors.

But the real genius is what happens after the purchase. By investing in flagship "experience stores" — like the fully renovated Shibuya location — MatsuKiyo turns inbound shoppers into brand ambassadors who post on social media. One visit becomes content. That content reaches future visitors. Future visitors come to MatsuKiyo. The loop keeps spinning.

Source: Ryutsu News (February 13, 2026)

The "Department Store Quality at Drug Store Prices" Effect

One of the buzziest topics in Japanese beauty communities is MatsuKiyo's private label (PB) products. The phrase "department store quality at drug store prices" has spread organically across social media, and it's not accidental — the company set a target of raising PB's share of sales to 15% (up from 12.7% in FY2023).

In brand growth terms, this is textbook UGC (User Generated Content) strategy: create a product that genuinely exceeds expectations, and let customers do the marketing for you. No ad spend required.

Source: Business Insider Japan (September 4, 2024)

M&A: Adding Shinseido Pharmacy to the Family

In October 2025, MatsuKiyo CC acquired Shinseido Pharmacy — a Kyushu-based chain — bringing total group stores to 3,618 locations. Beyond the immediate sales boost, this expands the brand's geographic footprint into regions it had limited presence in before.

Source: Ryutsu News (February 13, 2026)

One Thing to Watch

Not everything is perfect. The Q4 operating profit margin slipped from 7.9% to 7.4% year-on-year, as new consolidation costs and rising labor expenses put pressure on profitability. Scaling up while maintaining margins is the challenge ahead.

Sources: Kabutan News (May 13, 2026), WWD Japan (May 13, 2026)

Sugi Pharmacy: The "We're Part of Your Life" Brand

The Biggest Move This Year: Acquiring I&H

If MatsuKiyo's story this year is about brand elevation, Sugi's story is about bold M&A.

In September 2024, Sugi Holdings acquired I&H — a dispensing pharmacy chain operating over 500 locations across Japan under names including "Hanshin Chozai Pharmacy" — taking a 66.72% voting stake. The full-year contribution from I&H is a major driver of the ＋15.1% sales growth.

The combination is strategically powerful: Sugi's neighborhood pharmacy expertise meets I&H's hospital-front dispensing and specialist medical know-how. As Executive Officer Makoto Kasai put it: "Both merchandise and dispensing performed well. We're seeing a gradual increase in higher-value prescriptions."

Sources: Nikkei Shimbun (February 27, 2024, April 10, 2025)

Opening 110 New Stores in a Single Year

110 new store openings. 46 closures. 72 dispensing pharmacies acquired from I&H. 217 existing store renovations. At year-end, the group had 2,321 locations in total.

The renovations — focused on expanding food sections and enlarging dispensing areas — are showing up in the numbers: existing store same-store sales for merchandise were up ＋4% year-on-year.

Sources: Ryutsu News (April 9, 2026), Nikkei Shimbun (October 9, 2025)

Inbound Shoppers Love Sugi Too — For Different Reasons

Sugi Pharmacy is also capturing inbound demand in Tokyo and Osaka. What's interesting is why. As one company representative explained: "Compared to department stores, our price range is more accessible, and we're continuing to attract demand."

While MatsuKiyo draws visitors partly through brand appeal and beauty curation, Sugi wins on practical value — a wide selection of everyday products at honest prices. Different positioning, same growing market.

Sources: Nikkei Shimbun (July 10, 2025, October 9, 2025)

Digital + Physical: One-to-One Marketing via the Sugi App

Sugi's loyalty app is doing real work. Personalized coupons, targeted promotions, and tailored product recommendations are helping drive repeat visits and basket size. In a hyper-competitive retail landscape, data-driven one-to-one marketing is becoming a meaningful differentiator.

Sources: Nikkei Shimbun (October 9, 2025), Ryutsu News (June 27, 2024)

The Heart of Sugi's Strategy: What Is "Dominant Strategy" and Why Does It Matter?

If there's one concept that defines Sugi Pharmacy's competitive edge, it's their dominant strategy (ドミナント戦略 — dominant senryaku in Japanese).

Saturating a Region, One Neighborhood at a Time

The idea is straightforward: instead of spreading stores evenly across the country, concentrate them intensively in specific regions. The goal is to become so ubiquitous in a given area that customers never need — or want — to go anywhere else.

Sugi focuses on the Kanto (Greater Tokyo), Tokai (Nagoya area), Kansai (Osaka/Kobe), and Hokuriku regions. The result: #1 in number of insurance-covered pharmacies in Aichi, Tokyo, and Osaka.

Source: Sugi Pharmacy (Yakukya-ri Career Navigator Interview)

The "Core Store" Model

What makes Sugi's approach more sophisticated than simple cluster-opening is the "core store" (核店舗) model. Within a cluster of roughly 10 stores serving one local market, one location is designated as the hub. That core store takes the lead in building relationships with local hospitals, care facilities, and government health programs — becoming the anchor of a local healthcare network.

At this point, calling Sugi a "drug store" undersells what it actually is. It's closer to a node in a regional healthcare infrastructure.

Source: Nikkan Kogyo Shimbun (January 25, 2018)

It Fits Perfectly With Japan's National Healthcare Direction

Here's where things get really interesting from a strategic perspective. Japan is actively pushing a policy framework called the Community-Based Integrated Care System (地域包括ケアシステム) — the idea that people should be able to live in their own communities, supported by seamlessly connected medical, long-term care, and daily living services, right through to end of life.

Sugi's dominant strategy aligns almost perfectly with this vision. The more Japan leans into community-based healthcare, the more valuable it becomes to have a Sugi Pharmacy within walking distance. The company is building a business model that gets more valuable as the country ages.

Source: Sugi Pharmacy (Yakukya-ri Career Navigator Interview)

The Practical Benefits of Going Dense

Concentrating stores in one area creates some very tangible operational advantages:

• Lower logistics costs: delivery routes become more efficient when stores are clustered

• More effective advertising: local campaigns reach more of the target market per yen spent

• Competitive moat: once Sugi saturates an area, competitors face a much higher bar to enter profitably

• Operational flexibility: staff can cover nearby stores quickly when someone calls in sick

Source: City Life NEWS (September 9, 2019)

So, Which Strategy Is Better? (A Brand Growth Perspective)

Here's the part I find most fascinating.

MatsuKiyo: Building a Brand People Love

Everything MatsuKiyo does — cosmetics, PB products, inbound experience stores, social media buzz — points in one direction: "Shopping at MatsuKiyo should feel like a treat."

The organic spread of "department store quality at drug store prices" is a perfect example of UGC-driven brand growth. Customers become fans. Fans become advocates. Advocates attract new customers — without a single paid ad. That flywheel, once spinning, is extraordinarily powerful.

MatsuKiyo's model: build a brand people actively choose because they love it. The emotional connection creates loyalty, repeat purchase, and word-of-mouth that money can't buy.

Sugi: Building Infrastructure People Can't Leave

Sugi's approach is fundamentally different. The goal isn't to be loved — it's to be indispensable.

By embedding deeply into local healthcare networks through dominant strategy and dispensing pharmacy integration, Sugi creates high switching costs. Once a patient's prescription history is at the local Sugi, once their doctor's office is next door to a Sugi, once the nearest pharmacy within walking distance is Sugi — leaving requires real effort.

Sugi's model: build structural stickiness so that loyalty isn't a feeling — it's a fact of daily life.

Both Are Right

"So which is the correct strategy?" Neither. Both. It depends.

MatsuKiyo's strength is its urban footprint and beauty heritage. Sugi's strength is its community healthcare positioning and regional density. Each company chose the strategy that fits their assets, customers, and competitive environment — and then executed relentlessly.

The fact that both crossed ¥1 trillion proves something important: in brand strategy, there is no single winning formula. There are only strategies well-matched to context, and the discipline to follow through.

What to Watch Next

MatsuKiyo CC: The Q4 operating margin dip and rising costs are the near-term challenge. Can the company sustain its 6-year streak of record profits while absorbing integration costs? Also worth watching: progress toward the company's international expansion (targeting ¥100B in overseas sales).

Sugi Holdings: With the one-time I&H accounting effect gone, FY2027 will reveal Sugi's true earning power (projected net income: ¥32.8B, down 27.1%). The speed of the Seki Pharmacy subsidiary integration — originally planned for 5 years, completed in 6 months — shows the company's M&A ambitions aren't slowing down.

The bigger picture: Tsuruha Holdings and Welcia Holdings are merging to create a ¥2 trillion-plus mega-group. Japan's drug store landscape is shifting from "two ¥1 trillion players" to "one ¥1 trillion club vs. one ¥2 trillion giant." The next chapter is just beginning.

In Summary

• MatsuKiyo CC FY2026: Net sales ¥1,117.4B (＋5.3%), record profits for 6th straight year. Cosmetics, inbound, and PB brand strategy all firing

• Sugi Holdings FY2026: Net sales ¥1,010.3B (＋15.1%), first-ever ¥1 trillion milestone. I&H acquisition + dominant strategy accelerating growth

• Same destination, completely different journeys

• "Loved" vs. "Can't Live Without" — both are legitimate, powerful brand strategies when built on genuine competitive strengths

Sources

• MatsuKiyo CC IR (FY2026 Earnings, announced May 13, 2026)

• Sugi Holdings IR (FY2026 Earnings, announced April 9, 2026)

• Nikkei Shimbun (various dates)

• Ryutsu News (February 13, 2026; April 9, 2026)

• WWD Japan (May 13, 2026)

• Business Insider Japan (September 4, 2024)

• City Life NEWS (September 9, 2019)

• Yakukya-ri Career Navigator, Sugi Pharmacy Executive Interview

• Nikkan Kogyo Shimbun (January 25, 2018)

• METI (Ministry of Economy, Trade and Industry), Commercial Dynamics Survey (April 30, 2026)

※ All figures and citations in this article are based on official IR disclosures and published media reports. Please refer to original sources before making any investment decisions.

#DrugStore #MatsuKiyo #SugiPharmacy #MatsuKiyoCC #SugiHoldings #JapanRetail #Earnings2026 #JapanBusiness

#RetailIndustry #IndustryAnalysis #BusinessStrategy #MergersAndAcquisitions #Inbound #InboundTourism #PharmacyBusiness #HealthcareRetail #JapanEconomy

#BrandStrategy #BrandGrowth #DominantStrategy #GrowthStrategy #PrivateLabel #DigitalMarketing #LTV #UGC #CustomerLoyalty #MarketingStrategy #OneToOneMarketing

#Business #Marketing #Branding #Retail #Healthcare #Japan #JapanMarket #Ecommerce #ConsumerBehavior